Register to receive a free US Market Report Suite for Orthopedic Soft Tissue Repair and Sports Medicine report synopsis and brochure
Atreon Orthopedics, an orthopedic medical device company, announced that they have been granted FDA clearance on its proprietary product, the Rotium™ Bioresorbable Wick on March 19, 2019. The Rotium™ Bioresorbable Wick supports the regeneration in the healing of rotator cuff injuries.
This product acts to help reattach the tendon to the bone. In an animal research study, results in both an acute and chronic sheep model showed substantial improvements in the tenacity of the repaired tendon with using the Rotium Bioresorbable Wick, compared to not using the Rotium.
“To receive the second FDA clearance in a year, in two different clinical areas, tells us we are on the right track in developing our regeneration technology platform,” said Ross Kayuha, CEO of Atreon Orthopedics. “We saw impressive success with this product in both acute and chronic animal trials, and are looking forward to how this can help people who are recovering from rotator cuff injuries.”
According to research reported by iData Research, the overall U.S. orthopedic soft tissue repair market was valued at over $2.23 billion in 2019. This is expected to increase over the forecast period to reach $3 billion. Overall, the U.S. orthopedic soft tissue repair market is projected to experience modest growth over the forecast period, largely limited by the longer durations of some of the procedures. Although arthroscopy offers many benefits when compared to open or mini-open surgeries, the operating time for arthroscopy is much longer. This limiting factor can be solved by innovations in products, such as knotless suture anchors.
For Further Information
More on the orthopedic soft tissue repair market in the U.S. can be found in a series of reports published by iData Research entitled the U.S Market Report Suite for Orthopedic Soft Tissue Repair and Sports Medicine.
